home · filing · 0001628280-25-021506
8-K filed May 1, 2025, 7:59 PM ET
ticker FHTX
CIK 0001822462
leadership
confidence high
sentiment neutral
materiality 0.30
Foghorn Therapeutics appoints Neil Gallagher and Stuart Duty to Board of Directors
Foghorn Therapeutics Inc.
Stuart Duty and Neil Gallagher appointed effective May 1, 2025 as Class II directors.
Each granted initial option to purchase 50,000 shares vesting over three years.
Duty to serve on Audit Committee; Gallagher on Science Committee.
Duty receives annual cash retainers $40,000 board + $7,500 audit; Gallagher $40,000 + $5,000 science.
Audit Committee now has three independent members, regaining Nasdaq compliance.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-05-01
Filed May 1, 2025, 7:59 PM ET
appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.
Effective 2025-05-01
Filed May 1, 2025, 7:59 PM ET
appointed Stuart Duty to the Board, effective May 1, 2025.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Neil J. Gallagher was appointed as Director at Foghorn Therapeutics Inc..
Action appointed
Role Director
Exact text from the filing
appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Stuart Duty was appointed as Director at Foghorn Therapeutics Inc..
Action appointed
Role Director
Exact text from the filing
appointed Stuart Duty to the Board, effective May 1, 2025.
View on SEC.gov
Source: SEC EDGAR
accession 0001628280-25-021506
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.